Hypertension in pregnancy

Current Atherosclerosis Reports

Volumn 16, Issue 3, 2014, Pages

  Vest, Amanda R ^a   Cho, Leslie S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenic; Antiangiogenic; Antihypertensives; Eclampsia; Gestational; Hypertension; Placenta; Preeclampsia; Pregnancy

Indexed keywords

MAGNESIUM SULFATE; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT;

ANGIOGENESIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CYTOTROPHOBLAST; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECLAMPSIA; ENDOTHELIAL DYSFUNCTION; HELLP SYNDROME; HUMAN; MASS SCREENING; MATERNAL HYPERTENSION; NONHUMAN; PATIENT MONITORING; PLACENTA PERFUSION; PRACTICE GUIDELINE; PREECLAMPSIA; PROGNOSIS; PROPHYLAXIS; PROTEINURIA; REVIEW; CLASSIFICATION; DISEASE MANAGEMENT; FEMALE; GESTATIONAL AGE; HYPERTENSION; MATERNAL MORTALITY; MATERNAL WELFARE; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PREGNANCY; PREGNANCY COMPLICATION; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ANGIOGENESIS INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; DISEASE MANAGEMENT; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; MATERNAL MORTALITY; MATERNAL WELFARE; MONITORING, PHYSIOLOGIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84892908990     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0395-8     Document Type: Review

References (92)

1. • Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The eighth report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011;118 Suppl 1:1-203. This is the most recent detailed and comprehensive report on pregnancy-associated mortalities from the UK's Confidential Enquiry into Maternal Deaths. It also identifies "near miss" events and opportunities for improvement.
2. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1-22.
3. Tanaka M, Jaamaa G, Kaiser M, Hills E, Soim A, Zhu M, et al. Racial disparity in hypertensive disorders of pregnancy in New York state: a 10-year longitudinal population-based study. Am J Public Health. 2007;97(1):163-70. (Pubitemid 46067699)
4. Magee LA, Helewa M, Moutquin J-M, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-S48.
5. Redman CWG. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97(23):1967-9.
6. Regitz-Zagrosek V, Lundqvist CB, Borghi C, Cifkova R, Ferreira R, Foidart J-M, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147-97.
7. •• American College of Obstetricians and Gynecologists. Hypertension in pregnancy. http://www.acog.org/Resources-And-Publications/Task- Force-and-Work-Group-Reports/Hypertension-in-Pregnancy. 2013. The most recent practice guidelines from the ACOG summarize the current body of research in the field and offer comprehensive recommendations. Of note, this iteration of the guidelines emphasizes the potential for preeclampsia/eclampsia to occur in the absence of proteinuria and the diagnostic criteria have been updated to reflect this recognition.
8. Lenfant C. Working group report on high blood pressure in pregnancy. J Clin Hypertens Greenwich. 2001;3(2):75-88.
9. Mattar F, Sibai BM. Eclampsia VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol. 2000;182(2):307-12. (Pubitemid 30127340)
10. Chronic hypertension in pregnancy. Practice bulletin. Am Coll Obstet Gynecol. 2012;125:1-12.
11. Knight M. Eclampsia in the United Kingdom 2005. BJOG. 2007;114(9):1072-8. (Pubitemid 47247026)
12. Hirshfeld-Cytron J, Lam C, Karumanchi SA, Lindheimer M. Late postpartum eclampsia: examples and review. Obstet Gynecol Surv. 2006;61(7):471-80. (Pubitemid 43970456)
13. Duckitt K. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.BMJ. 2005;330(7491):565.
14. Bigelow CA, Pereira MGA, Warmsley A, Cohen MJ, Getrajdman MC, Moshier ME, et al. Risk factors for new-onset late postpartum preeclampsia in women without prior history of preeclampsia. Am J Obstet Gynecol. 2013. doi:10.1016/j.ajog. 2013.11.004.
15. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med. 2008;18(5):186-94.
16. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG. 2008;115(12):1465-72.
17. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005. (Pubitemid 44343543)
18. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim K-H. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197(1):28.e1-6.
19. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137-42. (Pubitemid 46986022)
20. Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol. 2008;35(4):631-4. (Pubitemid 351500058)
21. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006;194(2):551-6. (Pubitemid 43183715)
22. Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol. 2005;193(1):16-22. (Pubitemid 40991821)
23. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension. 2010;55(2):380-5.
24. Adali E, Kurdoglu M, Adali F, Cim N, Yildizhan R, Kolusari A. The relationship between brachial artery flow-mediated dilatation, high sensitivity C-reactive protein, and uterine artery Doppler velocimetry in women with pre-eclampsia. J Clin Ultrasound. 2011;39(4):191-7.
25. Saftlas AF. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol. 2003;157(12):1108-14. (Pubitemid 36682302)
26. Robillard PY, Hulsey TC, Perianin J, Janky E, Miri EH, Papiernik E. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet. 1994;344(8928):973-5. (Pubitemid 24306548)
27. Smith GN, Walker M, Tessier JL, Millar KG. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obstet Gynecol. 1997;177(2):455-8. (Pubitemid 27385730)
28. Croy BA, He H, Esadeg S, et al. Uterine natural killer cells; insight into their cellular and molecular biology from mouse modeling. Reproduction. 2003;136:149-60. (Pubitemid 36987161)
29. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-83. (Pubitemid 38364626)
30. • Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123(24):2856-69. This is an excellent review of the pathophysiology of preeclampsia, and outlines the current knowledge regarding the lifetime cardiovascular risk for women with a preeclamptic pregnancy.
31. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-99. (Pubitemid 40311367)
32. Poon LCY, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812-8.
33. Yu CKH, Smith GCS, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193(2):429-36. (Pubitemid 41159538)
34. • Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121-31. This is a prospective multicenter study testing the diagnostic accuracy of low plasma PlGF concentration in women presenting with suspected preeclampsia. The high sensitivity of this diagnostic strategy, particularly in women presenting before term, offers a realistic opportunity to translate preeclampsia biochemical research into improved clinical management.
35. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197(1):35.e1-7.
36. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early preeclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27(1):13-7. (Pubitemid 43129084)
37. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 2011;32(8):598-602.
38. D'Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM. Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol. 2005;106(2):340-4. (Pubitemid 41023273)
39. Bellomo G, Venanzi S, Saronio P, Verdura C, Narducci PL. Prognostic significance of serum uric acid in women with gestational hypertension. Hypertension. 2011;58:704-8.
40. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;2, CD004659.
41. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006;3, CD001059.
42. Levine RJ, Hauth JC, Curet LB, Sibai BM. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69-76. (Pubitemid 27284391)
43. Rumiris D, Purwosunu Y, Wibowo N, Farina A, Sekizawa A. Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status. Hypertens Pregnancy. 2006;25(3):241-53. (Pubitemid 44655661)
44. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 2006;367(9517):1145-54.
45. Roberts JM, Myatt L, Spong CY, Thom EA. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Eng J Med. 2010;362:1282-91.
46. • National Collaborating Centre for Women's and Children's Health. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. Clinical guideline no. 107. London: National Institute for Health and Clinical Excellence; 2010. These are detailed clinical guidelines from the UK for the contemporary management of preeclampsia, including cost analyses and specific guidance on antihypertensive medication strategies.
47. Conde-Agudelo A, Althabe F, Belizan JM, Kafury-Goeta AC. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am J Obstet Gynecol. 1999;181:1026-35. (Pubitemid 29503633)
48. England L. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am J Obstet Gynecol. 2002;186(5):1035-40.
49. Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, Klebanoff M, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. N Engl J Med. 1998;339(10):667-71. (Pubitemid 28402091)
50. Catov JM, Nohr EA, Olsen J, Ness RB. Chronic hypertension related to risk for preterm and term small for gestational age births. Obstet Gynecol. 2008;112(2 Pt 1):290-6.
51. Hedderson MM, Ferrara A. High blood pressure before and during early pregnancy is associated with an increased risk of gestational diabetes mellitus. Diabetes Care. 2008;31(12):2362-7.
52. Waterstone M. Incidence and predictors of severe obstetric morbidity: case-control study. Commentary: obstetric morbidity data and the need to evaluate thromboembolic disease. BMJ. 2001;322(7294):1089-94.
53. Maternal and Child Health Research Consortium. Confidential enquiry into stillbirths and deaths in infancy: 6th annual report, 1 January-31 December 1997. London: Maternal and Child Health Research Consortium; 1999.
54. Magee L, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;4, CD004351.
55. Chames MC, Haddad B, Barton JR, Livingston JC, Sibai BM. Subsequent pregnancy outcome in women with a history of HELLP syndrome at ≤28 weeks of gestation. Am J Obstet Gynecol. 2003;188(6):1504-8. (Pubitemid 36741280)
56. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991;165(5 Pt 1):1408-12.
57. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol. 2009;114(5):961-70.
58. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results fromcohort study. BMJ. 2003;326(7394):845.
59. Männistö T, Mendola P, Vääräsmäki M, Järvelin M-R, Hartikainen A-L, Pouta A, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127(6):681-90.
60. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
61. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJP. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki Birth Cohort Study. Stroke. 2009;40(4): 1176-80.
62. Wikström A-K, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112(11):1486-91. (Pubitemid 43961234)
63. Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG. 2003;110(11):1029-31. (Pubitemid 37338493)
64. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation. 2010;122(6):579-84.
65. Parvin S, Samsuddin L, Ali A, Chowdhury SA, Siddique I. Lipoprotein (a) level in pre-eclampsia patients. Bangladesh Med Res Counc Bull. 2011;36(3):97-9.
66. Robbins CL, Dietz PM, Bombard J, Valderrama AL. Gestational hypertension: a neglected cardiovascular disease risk marker. Am J Obstet Gynecol. 2011;204(4):336.e1-9.
67. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update. J Am Coll Cardiol. 2011;57(12):1404-23.
68. Martin JN, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246-54. (Pubitemid 40229437)
69. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007; 1:1-162.
70. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355(9198):87-92. (Pubitemid 30068551)
71. Cifkova R. Why is the treatment of hypertension in pregnancy still so difficult? Expert Rev Cardiovasc Ther. 2011;9(6):647-9.
72. Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al. The control of hypertension in pregnancy study pilot trial. BJOG. 2007;114(6):770-e20. (Pubitemid 46788637)
73. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-9. (Pubitemid 12179934)
74. Sandström B. Antihypertensive treatment with the adrenergic beta-receptor blocker metoprolol during pregnancy. Gynecol Invest. 1978;9(4):195-204. (Pubitemid 9141370)
75. Orbach H, Matok I, Gorodischer R, Sheiner E. Hypertension and anti-hypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol. 2012;208(4):301.e1-6.
76. •• Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;(7):CD001449. This is a Cochrane review of 35 trials (3, 573 women) of pharmacologic therapies to treat very high BP during pregnancy. Although the analysis ultimately concludes that there is no compelling evidence to recommend one agent over another at this time, the synthesis of existing comparative data is very useful in guiding individualized patient care decisions.
77. Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women. Curr Hypertens Rep. 2011;13(5): 338-46.
78. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-60. (Pubitemid 37330398)
79. Sass N, Itamoto CH, Silva MP, Torloni MR, Atallah AN. Does sodium nitroprusside kill babies? A systematic review. Sao Paulo Med J. 2007;125(2):108-11. (Pubitemid 47099218)
80. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after firsttrimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-51. (Pubitemid 43855047)
81. Schimmel MS, Eidelman AI, Wilschanski MA, Shaw D, Ogilvie RJ, Koren G, et al. Toxic effects of atenolol consumed during breast feeding. J Pediatr. 1989;114(3):476-8. (Pubitemid 19083836)
82. ACOG Committee on Practice Bulletins - Obstetrics. ACOG practice bulletin no. 33, diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159-67.
83. Altman D, Carroli G, Duley L, Farrell B, Moodley J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-90. (Pubitemid 34615765)
84. McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev. 2004;1, CD000201.
85. Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev. 2005;4, CD003514.
86. Friedman SA, Schiff E, Lubarsky SL, Sibai BM. Expectant management of severe preeclampsia remote from term. Clin Obstet Gynecol. 1999;42(3):470-8. (Pubitemid 30017270)
87. Sibai B. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102(1):181-92. (Pubitemid 36792143)
88. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Smith GD, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ. 2007;335(7627):978-8.
89. O'Brien TE, Ray JG, Chan W-S. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. 2003;14(3):368-74. (Pubitemid 40417091)
90. Facchinetti F, Allais G, Nappi RE, D'Amico R, Marozio L, Bertozzi L, et al.Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia. 2009;29(3):286-92.
91. Toh SY, Zarshenas N, Jorgensen J. Prevalence of nutrient deficiencies in bariatric patients. Nutrition. 2009;25(11-12):1150-6.
92. Kumar A, Basra M, Begum N, Rani V, Prasad S, Lamba AK, et al. Association of maternal periodontal health with adverse pregnancy outcome. J Obstet Gynaecol Res. 2013;39(1):40-5.